Previous Page  6 / 10 Next Page
Information
Show Menu
Previous Page 6 / 10 Next Page
Page Background

Recent Changes to Market

Participant Acquisition Premium

Guidance

Valuation Vantage

Fall 2016 | 6

In November 2015, The Appraisal Foundation’s Working Group

on Control Premiums (“Working Group”) issued an exposure

draft on the measurement and application of market participant

acquisition premiums (“MPAP”) after receiving feedback

pertaining to its discussion draft questions. The exposure draft

provides a more defined framework to determine how and when

to use control premiums as there is significant diversity in how

control premiums currently are applied for goodwill impairment

step 1 test purposes and other financial reporting purposes. In

2008, the SEC raised concerns that control premiums may be

inflated by public companies to avoid goodwill impairments. The

SEC requires justification when control premiums appear to be

inflated.

The Working Group added to the exposure draft further discussion

regarding the economic benefits to analyze in determining an

MPAP. This includes possible economic benefits to analyze in

determining a required rate of return/discount rate. In particular,

the Working Group added the following concepts that valuation

specialists may consider analyzing to reflect the appropriate

market participant’s perspective when estimating a size premium

to build to a required rate of return/discount rate:

1. As a practical expedient, valuation specialists could

bookend their income approach using the differing possible

perspectives of market participant’s risk to generate two

valuation indications—one reflecting the target’s size and

another reflecting the combined entity’s size. The valuation

specialist selects a point within the range, taking into

consideration the accounting standards requiring the analysis.

2. The valuation specialist may apply other valuation techniques

under the market or cost approaches to reveal a point

in a range where there is the greatest consensus across

approaches thereby implying the stronger size premium case.

3. The valuation specialist may calibrate the risk measure by

reviewing the accounting exercise (e.g. business combination

valuation) that was recorded for the subject company.

4. The valuation specialist may calibrate the risk measure by

reviewing the accounting exercise (e.g. business combination

valuation) that was recorded for comparable companies.

In analyzing observed transaction premiums from public

companies, the following factors to consider in determining an

MPAP were added to the exposure draft:

1. Stated Rationale for Transaction - When available,

analysts should review press releases and other

corporate announcements describing the transaction

to determine if the price paid (and therefore the multiples

and premiums observed) reflects any buyer-specific

synergies, or if any other characteristics of the transaction

render it unsuitable for use in a fair value measurement.

2. Stock Price and Volume Fluctuations Prior to Announcement

- In some cases, the stock of the target company may

exhibit unusual volatility and/or increased trading volume

prior to the formal announcement of the transaction. The

existence of such phenomena may indicate that the implied

acquisition premium should be calculated with reference to

an earlier, unaffected stock price.

The Working Group also replaced its MPAP selection and

assessment example with the following examples:

1. The first example addresses a case in which an MPAP

is critical to the pass/fail result of the test.

2. The second example addresses the same company and

basic fact pattern, but assumes a significantly lower

carrying value, resulting in a test for which the MPAP is

not a determining factor.

Both examples’ tests are the same in terms of the main

methods considered. However, the level of detail provided

in support of MPAP-related assumptions in the second

example is reduced to reflect the lack of MPAP significance

in relationship to the test result. The final MPAP guidance is

expected to be issued in early 2017.

The final guidance is expected to be issued within the next year.